Sareum
Private Company
Total funding raised: $16.2M
Overview
Sareum Holdings PLC is a public, clinical-stage biotech developing novel kinase inhibitors with a primary focus on dual TYK2/JAK1 inhibition for autoimmune conditions and cancer. Its lead asset, SDC-1801, is advancing through Phase 2-enabling studies, while a second program targets the CHK1 kinase in oncology. Headquartered in Cambridge, UK, the company leverages its expertise in kinase biology to pursue best-in-class therapeutic candidates in high-value markets, though it remains pre-revenue and faces the typical risks of drug development.
Technology Platform
Discovery and development platform for next-generation, selective small-molecule kinase inhibitors, with a focus on dual TYK2/JAK1 inhibition and CHK1 inhibition.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
The TYK2/JAK1 space is competitive, with several companies (e.g., Bristol Myers Squibb with deucravacitinib, a TYK2 inhibitor; and others with dual inhibitors) advancing candidates. In CHK1 inhibition, multiple biotech and pharma entities are developing assets, often in combination regimens. Sareum's challenge is to differentiate its compounds on selectivity, potency, or clinical data.